Study of 0.1% Uracil Topical Cream (UTC) for the Prevention of Hand-Foot Syndrome
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- James Cantrell, MD
Birmingham Hematology/Oncology Associates
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Bruno Cancer Center
Birmingham, Alabama, United States
- Comprehensive Cancer Center
Palm Springs, California, United States
- Research Institute of Deaconess Clinic
Evansville, Indiana, United States
- Cancer Care Center
New Albany, Indiana, United States
- Kansas City Cancer Centers
Overland Park, Kansas, United States
- Signal Point Clinical Research Center
Middleton, Ohio, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Apr 2010
- Primary completion
- 31 Aug 2011
- Completion
- 30 Sept 2011
- Last update posted
- 8 Oct 2019
- Registered enrollment
- 18
- Registry id
- NCT01100463
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.